Ascentage Pharma raises $126m in 1st biotech IPO of 2025

Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to Bring Its Cancer Meds to the World
Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced cases of certain blood cancers.
Ascentage raises $126m in first biotech IPO of 2025
Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, raising $126 million for its pipeline of small-molecule cancer drugs.
Ascentage Pharma’s US Shares Climb After $126 Million IPO
Shares of Ascentage Pharma Group International pared earlier losses to rise 0.75% in the Chinese biopharmaceutical company’s US trading debut, after pricing its $126.4 million initial public offering at a discount to its Asian stock.
Ascentage Pharma CEO Dr. Yang on IPO
Dr. Dajun Yang, Ascentage Pharma CEO, joins 'Closing Bell Overtime' to talk today's IPO. Marilyn Manson won’t face sexual assault, domestic violence charges in LA
Obesity biotech Aardvark eyes IPO as Ascentage makes $126M Nasdaq debut
The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics
Ascentage Pharma raises $126M via U.S. IPO (update)
Ascentage Pharma Group (AAPG) (AAPGV) (ASPHF), which is backed by Takeda (TAK), has priced a $126M U.S. initial public offering. Read more here.
Chinese Biotech Ascentage Aims For $134M IPO
Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia and for certain types of chronic myeloid leukemia.
Ascentage Pharma raises $126m in first biotech IPO of 2025
The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood cancer.
Ascentage prices first biotech IPO of 2025, raising $126M
The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.
Takeda-backed Ascentage Pharma aims to raise $126 million in US IPO
Ascentage Pharma said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable Chinese firm to seek a listing in the U.S. this year.
Ascentage Pharma IPO opens flat
IPO began trading Friday on the NASDAQ. Shares opened at $17.25 per ADS, in line with the initial public offering (IPO) price of $17.25. The pharmaceutical company, already listed on the Main Board of the Stock Exchange of Hong Kong Limited under the code 6855.
FierceBiotech11h
Metsera eyes $289M IPO to fund phase 3 weight loss trial
Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...
The Business Journals5d
Rockville's Ascentage Pharma seeks to raise $134M in U.S. IPO
Its IPO is one of several on tap for the biotech ... plus royalties of 12% to 19% of net sales. Ascentage Pharma’s Rockville hub, totaling 6,520 square feet, is its only U.S. office.
U.S. IPO Weekly Recap: Venture Global Prices A Pared-Down IPO As More Sizable Deals Join The Pipeline
Seven IPOs and one SPAC priced this past week, as more sizable issuers filed to go public in the US. Read more here.
Ascentage Pharma ADSs to Begin Trading on Nasdaq
Ascentage Pharma Group said its American depositary shares were slated to begin trading on the Nasdaq Global Market on Friday, with its initial public offering priced at $17.25 per ADS.